Robert W. Baird initiated coverage of Omada Health with a rating of Neutral and set a new price target of $24.00

Evercore ISI initiated coverage of Omada Health with a rating of Outperform and set a new price target of $21.00

Morgan Stanley initiated coverage of Omada Health with a rating of Overweight and set a new price target of $25.00

Analyst initiated coverage of Omada Health with a rating of Overweight and set a new price target of $19.00

Barclays initiated coverage of Omada Health with a rating of Overweight and set a new price target of $21.00

Needham initiated coverage of Omada Health with a rating of Buy and set a new price target of $23.00

Goldman initiated coverage of Omada Health with a rating of Buy and set a new price target of $29.00

Canaccord Genuity initiated coverage of Omada Health with a rating of Buy and set a new price target of $27.00

SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual-first, between-visit health care provider, today announced the planned launch of its prescribing capability. After reporting 53% year-over-year member growth as of the end of Q3, the company is also expanding its offerings. A new option of prescribing and medication management of anti-obesity medications (AOM), including GLP-1s, will be available in Omada's evidence-based behavior change weight health program, to tailor support before, during, and after medication treatment. "Omada is preparing for the next era of obesity care - one with broader access to GLP-1 medications of various types and price p

Revenue of $68 million, up 49%; 53% Member GrowthSignificant Reduction in Net Loss and First Quarter of Positive Adjusted EBITDAAnnounces New GLP-1 Prescribing Offering SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Omada Health, Inc. (NASDAQ:OMDA), the virtual between-visit healthcare provider, today reported financial results for the third quarter ended September 30, 2025. 2025 Third Quarter Highlights Total members of 831,000, up 53% compared with the third quarter of 2024Revenue of $68 million, up 49% compared with the third quarter of 2024Prescribing offering: announced plans to launch a new prescribing offering that will combine Omada's evidence-based behavior change program

SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, announced it will present two posters at ObesityWeek 2025 highlighting the potential impact of Omada's behavior change program on members currently or previously on GLP-1 medications for weight loss. Together, these analyses suggest that engagement with Omada may enhance results for members who have been on GLP-1s for weight loss, whether they stay on the medication or not. Previous clinical studies have suggested that sustained weight loss leads to increased long-term health benefits,¹ including the reduction of comorbidities, and persistence on a GLP-1 is associate

SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced the appointment of Thomas Tsang, MD, MPH as Chief Medical Officer. Dr. Tsang brings extensive experience in academia, clinical care delivery, and health information technology. In this role, he will lead Omada's clinical organization while advancing clinical quality, outcomes, strategy, and innovation across Omada's multi-condition platform. "Dr. Tsang's exceptional track record in building a virtual care delivery platform makes him the ideal clinical leader to help drive Omada's next phase of growth," said Sean Duffy, CEO and Co-Founder of Omada Heal

SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its third quarter 2025 results on Thursday, November 6, 2025, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details A live audio webcast of the call will be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same link and will remain accessible for approximately 12 months. Those participating via conference call can pre-register using the following link: https://register-conf.media-ser

The approach defies the restrictive weight loss paradigm, with early results indicating increased meal tracking and member engagement1 with new real-time, personalized nutrition guidance SAN FRANCISCO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, launches Meal Map, a new nutrient-categorization tool that combines AI-powered instant feedback with human care teams to help members in its cardiometabolic programs understand the nutrient quality of their food choices. Built within Omada's Nutritional Intelligence capability, Meal Map is designed to help members make informed food choices, with an aim towards fostering confidence a

SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released results from a real-world analysis that showed 63% of Omada members maintained or continued to lose weight 12 months after discontinuing GLP-1s,1 challenging widespread assumptions of inevitable post-medication weight regain. Since the GLP-1 Care Track launched, Omada has supported more than 100,000 members taking GLP-1 medications. The retrospective analysis included 816 members in Omada's GLP-1 Care Track and examined GLP-1 discontinuation and subsequent weight change at 6, 9, and 12 months.1 At one year post-discontinuation members showed just 0.8% ave

SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data¹ demonstrating that patients who used Omada's virtual physical therapy (PT) program to address musculoskeletal (MSK) conditions, Omada for Joint & Muscle Health, had lower utilization of total medical care and reduced MSK-related costs and encounters on average at 6 and 12 months compared to patients who used in-person PT (IP-PT). This study is believed to be one of the first peer-reviewed healthcare claims analyses to compare costs and utilization of virtual PT (V-PT) and IP-PT in treating MSK conditions while also accounting for the cost of the vir

SAN FRANCISCO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference, taking place in New York, including a fireside chat on Tuesday, September 9, 2025, at 5:35 pm ET. The webcast will be available online at https://investors.omadahealth.com/news-events/events. A replay will also be available at the same link following the event. About Omada Health Omada Health is a virtual-first healthcare provider that nurtures lifelong health, one day at a time. Omada care teams implement clinically-validated behavi

Revenue of $61 million, up 49%52% Member Growth and Significant Progress Toward Profitability SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) --  Omada Health, Inc. (NASDAQ:OMDA), the virtual between-visit healthcare provider, today reported financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Highlights Total Members of 752,000, up 52% compared to the second quarter of 2024Revenue of $61 million, up 49% compared to the second quarter of 2024GLP-1 Companion Success, with strong growth in members being supported by Omada's GLP-1 companion programs - now available through two of the largest pharmacy benefit managers in the United StatesOmada Horizon Day: In M

4 - Omada Health, Inc. (0001611115) (Issuer)

4 - Omada Health, Inc. (0001611115) (Issuer)

4 - Omada Health, Inc. (0001611115) (Issuer)

4 - Omada Health, Inc. (0001611115) (Issuer)

4 - Omada Health, Inc. (0001611115) (Issuer)

4 - Omada Health, Inc. (0001611115) (Issuer)

4 - Omada Health, Inc. (0001611115) (Issuer)

4 - Omada Health, Inc. (0001611115) (Issuer)

4 - Omada Health, Inc. (0001611115) (Issuer)

4 - Omada Health, Inc. (0001611115) (Issuer)

10-Q - Omada Health, Inc. (0001611115) (Filer)

8-K - Omada Health, Inc. (0001611115) (Filer)

SCHEDULE 13G/A - Omada Health, Inc. (0001611115) (Subject)

SCHEDULE 13G - Omada Health, Inc. (0001611115) (Subject)

SCHEDULE 13G - Omada Health, Inc. (0001611115) (Subject)

10-Q - Omada Health, Inc. (0001611115) (Filer)

8-K - Omada Health, Inc. (0001611115) (Filer)

SCHEDULE 13G - Omada Health, Inc. (0001611115) (Subject)

8-K - Omada Health, Inc. (0001611115) (Filer)

424B4 - Omada Health, Inc. (0001611115) (Filer)

SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its third quarter 2025 results on Thursday, November 6, 2025, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details A live audio webcast of the call will be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same link and will remain accessible for approximately 12 months. Those participating via conference call can pre-register using the following link: https://register-conf.media-ser

SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results on Thursday, August 7, 2025, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details Those participating in the conference call can pre-register using the following link: https://register-conf.media-server.com/register/BIce129368a015484a8f39659a48a1631e. A live audio webcast of the call will also be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same l

SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, announced it will present two posters at ObesityWeek 2025 highlighting the potential impact of Omada's behavior change program on members currently or previously on GLP-1 medications for weight loss. Together, these analyses suggest that engagement with Omada may enhance results for members who have been on GLP-1s for weight loss, whether they stay on the medication or not. Previous clinical studies have suggested that sustained weight loss leads to increased long-term health benefits,¹ including the reduction of comorbidities, and persistence on a GLP-1 is associate

SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced the appointment of Thomas Tsang, MD, MPH as Chief Medical Officer. Dr. Tsang brings extensive experience in academia, clinical care delivery, and health information technology. In this role, he will lead Omada's clinical organization while advancing clinical quality, outcomes, strategy, and innovation across Omada's multi-condition platform. "Dr. Tsang's exceptional track record in building a virtual care delivery platform makes him the ideal clinical leader to help drive Omada's next phase of growth," said Sean Duffy, CEO and Co-Founder of Omada Heal

The approach defies the restrictive weight loss paradigm, with early results indicating increased meal tracking and member engagement1 with new real-time, personalized nutrition guidance SAN FRANCISCO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, launches Meal Map, a new nutrient-categorization tool that combines AI-powered instant feedback with human care teams to help members in its cardiometabolic programs understand the nutrient quality of their food choices. Built within Omada's Nutritional Intelligence capability, Meal Map is designed to help members make informed food choices, with an aim towards fostering confidence a

SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released results from a real-world analysis that showed 63% of Omada members maintained or continued to lose weight 12 months after discontinuing GLP-1s,1 challenging widespread assumptions of inevitable post-medication weight regain. Since the GLP-1 Care Track launched, Omada has supported more than 100,000 members taking GLP-1 medications. The retrospective analysis included 816 members in Omada's GLP-1 Care Track and examined GLP-1 discontinuation and subsequent weight change at 6, 9, and 12 months.1 At one year post-discontinuation members showed just 0.8% ave

SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data¹ demonstrating that patients who used Omada's virtual physical therapy (PT) program to address musculoskeletal (MSK) conditions, Omada for Joint & Muscle Health, had lower utilization of total medical care and reduced MSK-related costs and encounters on average at 6 and 12 months compared to patients who used in-person PT (IP-PT). This study is believed to be one of the first peer-reviewed healthcare claims analyses to compare costs and utilization of virtual PT (V-PT) and IP-PT in treating MSK conditions while also accounting for the cost of the vir

SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.2 Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.1 Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,3 while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in